IASLC全球调查:NSCLC的PD-L1检测实践
国际肺癌研究协会病理委员会于2019年1-5月对64国344名病理学家进行全球调查,评估PD-L1免疫组化实践。结果显示抗体克隆、检测方法、样本类型、周转时间和质控措施存在显著异质性,76%参与者使用至少一种实验室自建检测,部分缺乏质控、培训和标准化报告。
要点
- PD-L1检测在不同地区和实验室间存在显著异质性。
- 76%参与者使用至少一种实验室自建检测(LDT)。
- 部分参与者缺乏质控、评分培训和标准化报告。
核心结论
- PD-L1检测在抗体克隆、免疫组化方法、样本、周转时间和质控措施方面存在显著异质性。
- 相当少数参与者缺乏质控、正式培训和标准化报告,需要额外质控措施和培训机会。
研究设计与样本
- 国际肺癌研究协会病理委员会于2019年1月至5月进行的全球调查,包含分析前、分析中和分析后条件的问题。
- 共344名来自64个国家的病理学家参与,其中41%来自欧洲,24%来自北美,18%来自亚洲。
主要发现
- 除活检和切除标本外,75%参与者使用细胞块,11%使用涂片。
- 克隆22C3最常用(69%),其次是SP263(51%)。
- 22C3和SP263分别有40%和30%的使用者将其作为实验室自建检测(LDT)应用,76%的参与者开发了至少一种LDT。
- 一半参与者报告周转时间≤2天,13%报告≥5天。
- 质控(QA)、评分正式培训和标准化报告未实施的比例分别为18%、16%和14%。
临床怎么用
- 临床实践中需注意PD-L1检测的地区和实验室差异,鼓励采用质控、正式培训和标准化报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is required to determine the eligibility for pembrolizumab monotherapy in advanced NSCLC worldwide and for several other indications depending on the country. Four assays have been approved/ Communauté Européene-In vitro Diagnostic (CV-IVD)-marked, but PD-L1 IHC seems diversely implemented across regions and laboratories with the application of laboratory-developed tests (LDTs). METHOD: To assess the practice of PD-L1 IHC and identify issues and disparities, the International Association for the Study of Lung Cancer Pathology Committee conducted a global survey for pathologists from January to May 2019, comprising multiple questions on preanalytical, analytical, and postanalytical conditions. RESULT: A total of 344 pathologists from 64 countries participated with 41% from Europe, 24% from North America, and 18% from Asia. Besides biopsies and resections, cellblocks were used by 75% of the participants and smears by 11%. The clone 22C3 was most often used (69%) followed by SP263 (51%). They were applied as an LDT by 40% and 30% of the users, respectively, and 76% of the participants developed at least one LDT. Half of the participants reported a turnaround time of less than or equal to 2 days, whereas 13% reported that of greater than or equal to 5 days. In addition, quality assurance (QA), formal training for scoring, and standardized reporting were not implemented by 18%, 16%, and 14% of the participants, respectively. CONCLUSIONS: Heterogeneity in PD-L1 testing is marked across regions and laboratories in terms of antibody clones, IHC assays, samples, turnaround times, and QA measures. The lack of QA, formal training, and standardized reporting stated by a considerable minority identifies a need for additional QA measures and training opportunities.
引用
- Mino-Kenudson M, Le Stang N, Daigneault JB, et al. The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. J Thorac Oncol. 2021. PMID: 33662578. doi:10.1016/j.jtho.2020.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。